Tim Smith

In recently-presented data, ivarmacitinib was found to have decreased severity of moderate-to-severe eczema compared to placebo.

New late-breaking data showed that oral roflumilast treatment was both safe and efficacious against psoriasis, making it a potentially less expensive and convenient treatment alternative.

New late-breaking data supported prior results indicating that all primary and secondary endpoints were reached for the IL-4Rα antibody known as CBP-201 for atopic dermatitis patients.

New late-breaking data showed positive results for bimekizumab treatment of hidradenitis suppurativa, with higher response rates and a strong safety profile.

In research drawn from his conference presentation, Lim discussed the unique photoprotection needs of skin of color as well as some of the challenges faced by patients in this population.

Kwatra spoke about his team’s research into nemolizumab for prurigo nodularis in the OLYMPIA 2 trial, including the data and its implications for the future.

New data indicates that an oral TYK2 inhibitor known as NDI-034858 showed strong results for psoriasis patients in a recent phase 2b trial.

New data has indicated that patients with psoriasis who were not responding to ixekizumab or secukinumab responded well to risankizumab, an interleukin-23 inhibitor.

Late-breaking data on roflumilast cream for eczema patients in two phase 3 trials titled INTEGUMENT-1 and INTEGUMENT-2 showed strong results for the drug.

In a new interview, Eichenfield discussed the background of his presentation on late-breaking data from the INTEGUMENT-1 and INTEGUMENT-2 trials on roflumilast for atopic dermatitis.

Late-breaking phase 3 data on nemolizumab monotherapy indicates substantial improvement in key primary and secondary endpoints for prurigo nodularis patients.

Late-breaking data showed strong results for ruxolitinib cream as a treatment for vitiligo in the long-term extension of the TRuE-V1 and TRuE-V2 studies.

New late-breaking data showed positive results from the phase 2 trial on a novel septa-specific monoclonal antibody for HS patients.

Dupilumab showed strong results for uncontrolled moderate-to-severe hand and foot atopic dermatitis, meeting its primary and secondary endpoints in the trial.

In this interview segment, Kwatra describes his upcoming conference presentation on prurigo nodularis and some of the biggest takeaways from his presentation.

An interview segment with Lim in which he describes some key takeaways from his conference presentation on sunscreen, photoprotection, and phototherapy.

In his conference presentation ‘Phototherapy and Photoprotection,’ Lim describes some key takeaways and research on UV filter and photoprotection health effects.

In this interview segment, Damsky spoke more about his conference presentation on JAK inhibitors, describing his response to safety concerns and other information.

Damsky discussed his conference presentation on the application of JAK inhibitors on dermatologic conditions such as granuloma annulare and sarcoidosis.

A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.

New phase 3 trial data was announced by Dermavant Sciences indicating strong results for both efficacy and safety of tapinarof treatment for atopic dermatitis.

New research was conducted into treating Stevens-Johnson syndrome/toxic epidermal necrolysis patients with plasmapheresis before intravenous immunoglobulin therapy.

A new study indicated that body surface area predicted erythema-type chronic graft-vs-host disease survival more accurately than NIH Skin Scores.

Recent data highlighted the relationship between different blood types and acne severity, identifying correlations between specific groups.

A new post-hoc analysis used 5 clinical trials on dupilumab to assess the drug’s effectiveness with and without topical corticosteroids for atopic dermatitis/eczema patients.

New research assessed the association between perceived stress and cognitive function in Black and White adults, finding that stress screening for high-risk adults may be needed.

Data presented in a research letter suggests that medicinal-thermal waters found in a spring in Las Salinas (near Madrid) had positive effects on plaque psoriasis.

New data demonstrated that the combined use of prednisone and methotrexate saw positive results in hair regrowth for patients with alopecia totalis or alopecia universalis.

In a research letter, patient perspectives were explored regarding access to dermatology clinic notes, with more than half reporting improved understanding due to notes.

In another interview segment, Castells discussed the safety profile of avapritinib for indolent systemic mastocytosis, as well as future research.